Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 4513 - 4520 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCN2432 | Cyclo(Tyr-Leu) |
|
Cyclo(Tyr-Leu) shows cytotoxicity, antifungal,and anticoagulant activities.
|
|
| BCN2433 | Cyclo(Leu-Leu) |
|
Cyclo(Leu-Leu) is an efficient supramolecular catalyst.
|
|
| BCN2434 | Cyclo(Ile-Leu) |
|
Cyclo(Ile-Leu) shows cytotoxic activity in vitro.
|
|
| BCN2436 | Cyclo(Leu-Val) |
|
Cyclo(Leu-Val) is a cyclic dipeptide from the fermentation broth of F8712 strain.
|
|
| BCN2437 | Ganoderic acid D |
|
Ganoderic acid D treatment for 48h inhibits the proliferation of HeLa human cervical carcinoma cells with an IC(50) value of 17.3 +/- 0.3 microM.
|
|
| BCN2438 | Ganoderic acid N |
|
1. 23-Dihydroganoderic Acid N has anticancer effects.
|
|
| BCN2439 | Ganoderic acid Y |
|
1. Ganoderic acid Y significantly inhibits the replication of the viral RNA (vRNA) of EV71 replication through blocking EV71 uncoating.
|
|
| BCN2440 | Ganoderic acid Z |
|
1. Ganoderic acid zeta has cytotoxicity in vitro against Meth-A and LLC cell lines.
2. The binding affinities of ganoderic acid DM and Z (ΔGbind, −16.83 and−10.99 kcal mol−1) are comparable to that of current commercial drug oseltamivir (−23.62 kcal mol−1);Ganoderic acid DM is a potential source of anti-influenza ingredient, with novel binding pattern and advantage over oseltamivir, it has steric hindrance on the 150 cavity of N1 protein, and exerts activities across the H274Y and N294S mutations, is the attractive candidates of novel neuraminidase (NA) inhibitors. |
|